LUNG vs SOLV

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 12, 2026

LUNG

49.6
AI Score
VS
LUNG Wins

SOLV

44.9
AI Score

Investment Advisor Scores

LUNG

50score
Recommendation
HOLD

SOLV

45score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric LUNG SOLV Winner
Revenue 43.34M 4.22B SOLV
Net Income -23.73M 105.00M SOLV
Gross Margin 78.0% 56.5% LUNG
Net Margin -54.8% 2.5% SOLV
Operating Income -22.01M 262.00M SOLV
ROE -60.6% 2.2% SOLV
ROA -20.7% 0.7% SOLV
Total Assets 114.73M 14.24B SOLV
Cash 55.84M 403.00M SOLV
Debt/Equity 0.96 0.95 SOLV
Current Ratio 4.32 1.02 LUNG
Free Cash Flow -15.32M -129.00M LUNG

Relative Price Performance (Last 90 Days)

LUNG 1M: -19.2% · 3M: +30.3% SOLV 1M: +2.5% · 3M: +10.4%

Current Technical Phase

LUNG

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 38

RSI (14): 37.6 · Price: $1.85

SOLV

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 46

RSI (14): 45.9 · Price: $87.45

Fundamentals Snapshot

Metric LUNG SOLV
Market Cap
Forward P/E -2.0 12.1
Trailing P/E 11.0
Revenue (TTM)
Revenue Growth 0.0% 0.0%
Gross Margin 0.8% 0.5%
Operating Margin -0.4% 0.1%
EPS -1.15 7.97
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, LUNG is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.